Crooks P A, Rosenberg H E
J Med Chem. 1978 Jun;21(6):585-7. doi: 10.1021/jm00204a016.
Spiro[tetralin-2,2'-pyrrolidine] (13) and spiro[6-methoxytetralin-2,2'-pyrrolidine] (17) were prepared by initial Michael condensation of 2-nitrotetralin and 6-methoxy-2-nitrotetralin, respectively, with methyl acrylate to give 7 and 8, both of which could be reductively cyclized to 10 and 11, followed by LiAlH4 reduction. Spiro[indan-2,2'-pyrrolidine] (15) was prepared in an analogous manner form 2-nitroindan, and spiro[6-hydroxytetralin-2,2'-pyrrolidine] (19) was prepared by O-demethylation of 17. Compound 13 and its N-methyl derivative, 14, both showed good analgesic activity. Compounds 13-16 all possessed weak antidepressant properties, but neither 19 nor its N-methyl derivative 20 had any significant CNS activity.
螺[四氢萘-2,2'-吡咯烷](13)和螺[6-甲氧基四氢萘-2,2'-吡咯烷](17)的制备方法如下:首先分别使2-硝基四氢萘和6-甲氧基-2-硝基四氢萘与丙烯酸甲酯进行迈克尔缩合反应,得到7和8,二者均可经还原环化反应生成10和11,随后用氢化铝锂进行还原。螺[茚满-2,2'-吡咯烷](15)以类似方式由2-硝基茚满制备,螺[6-羟基四氢萘-2,2'-吡咯烷](19)通过17的O-去甲基化反应制备。化合物13及其N-甲基衍生物14均表现出良好的镇痛活性。化合物13 - 16均具有较弱的抗抑郁特性,但19及其N-甲基衍生物20均无任何显著的中枢神经系统活性。